Supernus Pharmaceuticals (SUPN) Insider & Congress Trades

Smart money at a glance

Filings to Oct 27, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 2 added, 1 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about SUPN filings

Are insiders buying or selling Supernus Pharmaceuticals Inc (SUPN) stock?

Neither. Supernus Pharmaceuticals Inc (SUPN) insiders filed no open-market purchases or sales in the 90 days to Oct 27, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SUPN recently?

None. No member of Congress disclosed a SUPN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SUPN smart-money data?

This summary uses filings available on Oct 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on SUPN

Lean long1 source:
- Funds
Lean short1 source:
- Politicians

Top traders
No tracked positions at the last update
Insiders
No recent insider filings found
Politicians
- Donald Trump, President, sold $15K–$50K, disclosed Sep 22
- Donald Trump, President, sold $15K–$50K, disclosed Jul 1
Lean short · thin0 buys · 2 salesExecutive
Executive branch filings. Amounts are filing ranges, not prices, and filings can lag the trade.
Funds
Lean long2 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about SUPN filings

Are insiders buying or selling Supernus Pharmaceuticals Inc (SUPN) stock?

Neither. Supernus Pharmaceuticals Inc (SUPN) insiders filed no open-market purchases or sales in the 90 days to Oct 27, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SUPN recently?

None. No member of Congress disclosed a SUPN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SUPN smart-money data?

Funds

What funds are doing

6 moves · 6 mo

Buys/Adds$127.8MSells/Trims$68.2M

Buys/Adds (2)

TS
Two Sigma
Q2 2026 13F
$41.1M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%
QR
Qube Research
Q2 2026 13F
$17.1M
added

Sells/Trims (1)

P7
Point72
Steven Cohen · Q2 2026 13F
$68.2M
sold
Signals like this: n=2234, 53% finished lower at D15, median -0.5% vs SPY -0.4%

3 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 3 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 3, 2026

Earnings came in 4.1% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 3, 2026

Period ending

Jun 30, 2026

Earnings per share

$0.53+4.10% beat

$0.51 expected

Revenue

$219.1M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Oct 29, 2026, in 2 days

Previous reports

Period ending	Reported	EPS / estimate	EPS surprise	Revenue / income	Surprise
Jun 30, 2026	Aug 3, 2026	$0.53 / $0.51Yahoo Finance	+4.10% beat	$219.1M No estimateSEC filing	Unavailable
Mar 31, 2026	May 5, 2026	$0.21 / $0.28Yahoo Finance	-24.51% miss	$207.7M No estimateSEC filing	Unavailable
Dec 31, 2025	Feb 24, 2026	$0.88 / $0.28Yahoo Finance	+$0.60 beat	$211.6M No estimate	Unavailable
Sep 30, 2025	Nov 4, 2025	$0.61 / $0.82Yahoo Finance	-25.89% miss	$192.1M No estimateSEC filing	Unavailable
Jun 30, 2025	Aug 5, 2025	$0.91 / $0.47Alpha Vantage	+93.62% beat	$165.5M No estimateSEC filing	Unavailable
Mar 31, 2025	May 6, 2025	$0.44 / $0.37Alpha Vantage	+18.92% beat	$149.8M No estimateSEC filing	Unavailable
Dec 31, 2024	Feb 25, 2025	$0.55 / $0.52Alpha Vantage	+5.44% beat	$661.8M No estimateYear ended Dec 31, 2024 · SEC filing	Unavailable
Sep 30, 2024	Nov 4, 2024	$1.10 / $0.44Alpha Vantage	+150.00% beat	$175.7M No estimateSEC filing	Unavailable

EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.

Open: $41.68
52-wk high: $59.68
High: $41.95
52-wk low: $37.54
Low: $39.96
Prev close: $42.07
Mkt cap: $2.37B
ROE: -10.5%
Fwd P/E: 20.2x
Beta: 0.55
P/S: 2.9x
P/B: 2.5x
Profit margin: -13.2%
Op margin: -2.5%

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -13.2%
Forward P/E: 20.16
Market cap: $2.4B

Valuation

P/S2.85
P/B2.53

Quality

Operating margin-2.5%
ROE-10.5%
ROA0.4%

Growth

Beta0.55

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

42balanced

20D volatility

42%annualized

52-week range

$40.70

$37.54$59.68

20D support

$37.54recent floor

20D resistance

$44.93recent ceiling

Returns

5D +7.4%20D -4.6%60D -10.8%

Price vs moving averages

SMA20 -2.8%SMA50 -5.8%SMA200 -14.4%

Volume pace

1.48xvs prior 20D

Smart money at a glance

Filings to Oct 27, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 2 added, 1 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about SUPN filings

Are insiders buying or selling Supernus Pharmaceuticals Inc (SUPN) stock?

Neither. Supernus Pharmaceuticals Inc (SUPN) insiders filed no open-market purchases or sales in the 90 days to Oct 27, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SUPN recently?

None. No member of Congress disclosed a SUPN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SUPN smart-money data?

13F: filed up to 45 days late.

Smart money on SUPN

Lean long1 source:
- Funds
Lean short1 source:
- Politicians

Top traders
No tracked positions at the last update
Insiders
No recent insider filings found
Politicians
- Donald Trump, President, sold $15K–$50K, disclosed Sep 22
- Donald Trump, President, sold $15K–$50K, disclosed Jul 1
Lean short · thin0 buys · 2 salesExecutive
Executive branch filings. Amounts are filing ranges, not prices, and filings can lag the trade.
Funds
Lean long2 added · 1 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about SUPN filings

Are insiders buying or selling Supernus Pharmaceuticals Inc (SUPN) stock?

Neither. Supernus Pharmaceuticals Inc (SUPN) insiders filed no open-market purchases or sales in the 90 days to Oct 27, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SUPN recently?

None. No member of Congress disclosed a SUPN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SUPN smart-money data?

Funds

What funds are doing

6 moves · 6 mo

Buys/Adds$127.8MSells/Trims$68.2M

Buys/Adds (2)

TS
Two Sigma
Q2 2026 13F
$41.1M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%
QR
Qube Research
Q2 2026 13F
$17.1M
added

Sells/Trims (1)

P7
Point72
Steven Cohen · Q2 2026 13F
$68.2M
sold
Signals like this: n=2234, 53% finished lower at D15, median -0.5% vs SPY -0.4%

3 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 3 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 3, 2026

Earnings came in 4.1% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 3, 2026

Period ending

Jun 30, 2026

Earnings per share

$0.53+4.10% beat

$0.51 expected

Revenue

$219.1M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Oct 29, 2026, in 2 days

Previous reports

Period ending	Reported	EPS / estimate	EPS surprise	Revenue / income	Surprise
Jun 30, 2026	Aug 3, 2026	$0.53 / $0.51Yahoo Finance	+4.10% beat	$219.1M No estimateSEC filing	Unavailable
Mar 31, 2026	May 5, 2026	$0.21 / $0.28Yahoo Finance	-24.51% miss	$207.7M No estimateSEC filing	Unavailable
Dec 31, 2025	Feb 24, 2026	$0.88 / $0.28Yahoo Finance	+$0.60 beat	$211.6M No estimate	Unavailable
Sep 30, 2025	Nov 4, 2025	$0.61 / $0.82Yahoo Finance	-25.89% miss	$192.1M No estimateSEC filing	Unavailable
Jun 30, 2025	Aug 5, 2025	$0.91 / $0.47Alpha Vantage	+93.62% beat	$165.5M No estimateSEC filing	Unavailable
Mar 31, 2025	May 6, 2025	$0.44 / $0.37Alpha Vantage	+18.92% beat	$149.8M No estimateSEC filing	Unavailable
Dec 31, 2024	Feb 25, 2025	$0.55 / $0.52Alpha Vantage	+5.44% beat	$661.8M No estimateYear ended Dec 31, 2024 · SEC filing	Unavailable
Sep 30, 2024	Nov 4, 2024	$1.10 / $0.44Alpha Vantage	+150.00% beat	$175.7M No estimateSEC filing	Unavailable

Open: $41.68
52-wk high: $59.68
High: $41.95
52-wk low: $37.54
Low: $39.96
Prev close: $42.07
Mkt cap: $2.37B
ROE: -10.5%
Fwd P/E: 20.2x
Beta: 0.55
P/S: 2.9x
P/B: 2.5x
Profit margin: -13.2%
Op margin: -2.5%

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -13.2%
Forward P/E: 20.16
Market cap: $2.4B

Valuation

P/S2.85
P/B2.53

Quality

Operating margin-2.5%
ROE-10.5%
ROA0.4%

Growth

Beta0.55

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

42balanced

20D volatility

42%annualized

52-week range

$40.70

$37.54$59.68

20D support

$37.54recent floor

20D resistance

$44.93recent ceiling

Returns

5D +7.4%20D -4.6%60D -10.8%

Price vs moving averages

SMA20 -2.8%SMA50 -5.8%SMA200 -14.4%

Volume pace

1.48xvs prior 20D

Supernus Pharmaceuticals Inc

Smart money at a glance

What do analysts expect?

Questions about SUPN filings

Smart money on SUPN

Questions about SUPN filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 4.1% above what analysts expected.

Estimated report: Oct 29, 2026, in 2 days

Previous reports

Is the business strong?

Price structure

Supernus Pharmaceuticals Inc

Smart money at a glance

What do analysts expect?

Questions about SUPN filings

Smart money on SUPN

Questions about SUPN filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 4.1% above what analysts expected.

Estimated report: Oct 29, 2026, in 2 days

Previous reports

Is the business strong?

Price structure

Supernus Pharmaceuticals Inc

Overview

Questions about SUPN filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals

Supernus Pharmaceuticals Inc

Overview

Questions about SUPN filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals